Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study

Metabolomics

Volumn 6, Issue 2, 2010, Pages 191-201

  Kaddurah Daouk, Rima ^a   Baillie, Rebecca A ^b   Zhu, Hongjie ^d   Zeng, Zhao Bang ^d   Wiest, Michelle M ^c   Nguyen, Uyen Thao ^c   Watkins, Steven M ^c   Krauss, Ronald M ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Rosa and Co LLC   (United States)

^c Tethys Bioscience   (United States)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Cardiovascular disease; Lipidomics; Metabolomics; Pharmacogenomics; Pharmacometabolomics; Simvastatin

Indexed keywords

EID: 77952091681     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-010-0207-x     Document Type: Article

References (36)

1. AHA. (2004). Heart disease and stroke statistics-2004 update. Dalls, TX: American Heart Association.
2. Baigent, C., Keech, A., Kearney, P. M., Blackwell, L., Buck, G., Pollicino, C., et al. (2005). Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet, 366, 1267-1278.
3. Bilheimer, D. W., Grundy, S. M., Brown, M. S., & Goldstein, J. L. (1983). Mevinolin stimulates receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Transactions of the Association of American Physicians, 96, 1-9.
4. Bonnet, J., Mcpherson, R., Tedgui, A., Simoneau, D., Nozza, A., Martineau, P., et al. (2008). Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (comparative atorvastatin pleiotropic effects) study. Clinical Therapeutics, 30, 2298-2313.
5. Cipollone, F., Fazia, M., Iezzi, A., Zucchelli, M., Pini, B., De Cesare, D., et al. (2003). Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation, 107, 1479-1485.
6. Engelmann, B., Brautigam, C., & Thiery, J. (1994). Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins. Biochemical and Biophysical Research Communications, 204, 1235-1242.
7. Farooqui, A. A., Ong, W. Y., & Horrocks, L. A. (2006). Inhibitors of brain phospholipase A2 activity: Their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacological Reviews, 58, 591-620.
8. Ferrucci, L., Cherubini, A., Bandinelli, S., Bartali, B., Corsi, A., Lauretani, F., et al. (2006). Relationship of plasma polyunsaturated fatty acids to circulating inflammatory markers. Journal of Clinical Endocrinology and Metabolism, 91, 439-446.
9. Goodenowe, D. B., Cook, L. L., Liu, J., Lu, Y., Jayasinghe, D. A., Ahiahonu, P. W., et al. (2007). Peripheral ethanolamine plasmalogen deficiency: A logical causative factor in Alzheimer's disease and dementia. Journal of Lipid Research, 48, 2485-2498.
10. Grundy, S. M. (2001). United States cholesterol guidelines 2001: Expanded scope of intensive low-density lipoprotein-lowering therapy. American Journal of Cardiology, 88, 23J-27J.
11. Grundy, S. M., Cleeman, J. I., Merz, C. N., Brewer, H. B., Jr, Clark, L. T., Hunninghake, D. B., et al. (2004). Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation, 110, 227-239.
12. Hahnel, D., Thiery, J., Brosche, T., & Engelmann, B. (1999). Role of plasmalogens in the enhanced resistance of LDL to copper-induced oxidation after LDL apheresis. Arteriosclerosis, Thrombosis, and Vascular Biology, 19, 2431-2438.
13. Jasinska, M., Owczarek, J., & Orszulak-Michalak, D. (2007). Statins: A new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacological Reports, 59, 483-499.
14. Jula, A., Marniemi, J., Ronnemaa, T., Virtanen, A., & Huupponen, R. (2005). Effects of diet and simvastatin on fatty acid composition in hypercholesterolemic men: A randomized controlled trial. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 1952-1959.
15. Klein-Platat, C., Drai, J., Oujaa, M., Schlienger, J. L., & Simon, C. (2005). Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. American Journal of Clinical Nutrition, 82, 1178-1184.
16. Laaksonen, R., Katajamaa, M., Paiva, H., Sysi-Aho, M., Saarinen, L., Junni, P., et al. (2006). A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS ONE, 1, e97.
17. Lawrence, M. B., & Zaugg, A. M. (2004). IMS health report. MM& M.
18. Lee, R. G., Kelley, K. L., Sawyer, J. K., Farese, R. V., Jr, Parks, J. S., & Rudel, L. L. (2004). Plasma cholesteryl esters provided by lecithin: cholesterol acyltransferase and acyl-coenzyme a: Cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circulation Research, 95, 998-1004.
19. Lessig, J., & Fuchs, B. (2009). Plasmalogens in biological systems: Their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. Current Medicinal Chemistry, 16, 2021-2041.
20. Liu, M., Bagdade, J. D., & Subbaiah, P. V. (1995). Specificity of lecithin: cholesterol acyltransferase and atherogenic risk: Comparative studies on the plasma composition and in vitro synthesis of cholesteryl esters in 14 vertebrate species. Journal of Lipid Research, 36, 1813-1824.
21. Ma, J., Folsom, A. R., Lewis, L., & Eckfeldt, J. H. (1997). Relation of plasma phospholipid and cholesterol ester fatty acid composition to carotid artery intima-media thickness: The atherosclerosis risk in communities (ARIC) study. American Journal of Clinical Nutrition, 65, 551-559.
22. Messner, T., Sihm, H., & Vessby, B. (1998). Fatty acid composition in serum among males 4-16 years after myocardial infarction. International Journal of Circumpolar Health, 57, 22-31.
23. Moilanen, T., Solakivi-Jaakkola, T., Viikari, J., Rasanen, L., Akerblom, H. K., Uhari, M., et al. (1986). Fatty acid composition of serum cholesteryl esters in relation to serum lipids and apolipoproteins in 3-18-year-old Finnish children and adolescents. Atherosclerosis, 59, 113-119.
24. Neidlinger, N. A., Larkin, S. K., Bhagat, A., Victorino, G. P., & Kuypers, F. A. (2006). Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. The Journal of Biological Chemistry, 281, 775-781.
25. Ozerova, I. N., Paramonova, I. V., Olfer'ev, A. M., Akhmedzhanov, N. M., Aleksandrova, M. A., & Perova, N. V. (2001). Effects of simvastatin on the phospholipid composition of high-density lipoproteins in patients with hypercholesterolemia. Bulletin of Experimental Biology and Medicine, 132, 763-765.
26. Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Jr, Kastelein, J. J., et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359, 2195-2207.
27. Rise, P., Ghezzi, S., Carissimi, R., Mastromauro, F., Petroni, A., & Galli, C. (2007). Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells. European Journal of Pharmacology, 571, 97-105.
28. Rise, P., Pazzucconi, F., Sirtori, C. R., & Galli, C. (2001). Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. Nutrition, Metabolism & Cardiovascular, 11, 88-94.
29. Sathyapalan, T., Atkin, S. L., & Kilpatrick, E. S. (2008). Variability of lipids in patients with type 2 diabetes taking statin treatment: Implications for target setting. Diabetic Medicine, 25, 909-915.
30. Simon, J. A., Lin, F., Hulley, S. B., Blanche, P. J., Waters, D., Shiboski, S., et al. (2006). Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: The cholesterol and pharmacogenetics (CAP) Study. American Journal of Cardiology, 97, 843-850.
31. Sotiriou, C. G., & Cheng, J. W. (2000). Beneficial effects of statins in coronary artery disease-beyond lowering cholesterol. Annals of Pharmacotherapy, 34, 1432-1439.
32. Storey, J. D., & Tibshirani, R. (2003). Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences of the United States of America, 100, 9440-9445.
33. Sundstrom, J., Lind, L., Vessby, B., Andren, B., Aro, A., & Lithell, H. (2001). Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation, 103, 836-841.
34. Watkins, S. M., Reifsnyder, P. R., Pan, H. J., German, J. B., & Leiter, E. H. (2002). Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. Journal of Lipid Research, 43, 1809-1817.
35. Yanagita, T., Yamamoto, K., Ishida, S., Sonda, K., Morito, F., Saku, K., et al. (1994). Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells. Clinical Therapeutics, 16, 200-208.
36. Zhou, Z., Rahme, E., & Pilote, L. (2006). Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. American Heart Journal, 151, 273-281.